インデックス付き
  • 学術雑誌データベース
  • Genamics JournalSeek
  • アカデミックキー
  • ジャーナル目次
  • 中国国家知識基盤 (CNKI)
  • シマゴ
  • Global Online Research in Agriculture (AGORA) へのアクセス
  • 電子ジャーナルライブラリ
  • レフシーク
  • 研究ジャーナル索引作成ディレクトリ (DRJI)
  • ハムダード大学
  • エブスコ アリゾナ州
  • OCLC-WorldCat
  • SWBオンラインカタログ
  • 仮想生物学図書館 (vifabio)
  • パブロン
  • ミアル
  • 大学補助金委員会
  • ジュネーブ医学教育研究財団
  • ユーロパブ
  • Google スカラー
このページをシェアする
ジャーナルチラシ
Flyer image

概要

A Return to Microbial Genomes in the Metagenome Age

Eric Altermann

Metagenomics has broadened significantly in microbial ecosystems, phylogenetic diversity and genetic complexity. In the course of only a few years microbial genomics has seen a dramatic rise from the 1.8 Megabase pair (Mbp) genome of the first free-living organism sequenced (Haemophilus influenzae Rd in 1995 [1]) to (meta) genome programmes now generating more than a Terabase pair of sequence data each. These advances have been made possible by increasingly more powerful sequencing technologies. Fluorescent slab-gel electrophoresis methods were replaced by capillary-based systems, which brought a significant increase in the level of throughput and automation. A step change came with the introduction of “sequencing by synthesis”. This technology was commercialised as ‘pyrosequencing’, notably by 454 Life Sciences. While initially providing only shorter read lengths of 100-200 nucleotides (nt), and having a lower base call quality and problems with homopolymeric stretches of nucleotides, it also delivered a leap in sequencing capacity (up to 400 Mbp per run) from capillary Sanger-based sequencing technologies. Since then a number of other next-generation sequencing platforms have been commercialised (such as Illumina, SOLID, Ion Torrent), each increasing the amount of sequence information gained per run (Illumina HiSeq2500 currently delivers up to 600 Gbp per run). While single molecule real time (SMRT) sequencing is still in its infancy, it is likely to be the “next big thing” and prototypes (mainly from Pacific Biosciences) are currently being trialled.